Overview

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy
Phase:
Phase 1
Details
Lead Sponsor:
Santen Inc.
Collaborator:
MacuSight, Inc.
Treatments:
Everolimus
Sirolimus